| Literature DB >> 24019924 |
Wisnumurti Kristanto1, Peter M A van Ooijen, Marijke C Jansen-van der Weide, Rozemarijn Vliegenthart, Matthijs Oudkerk.
Abstract
BACKGROUND: Many computed tomography (CT) studies have reported that lipid-rich, presumably rupture-prone atherosclerotic plaques can be characterized according to their Hounsfield Unit (HU) value. However, the published HU-based characterization criteria vary considerably. The present study aims to systematically analyze these values and empirically derive a hierarchical classification of the HU-based criteria which can be referred in clinical situation.Entities:
Mesh:
Year: 2013 PMID: 24019924 PMCID: PMC3760884 DOI: 10.1371/journal.pone.0073460
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Search strategy and result.
Characteristics of the included publications.
|
|
|
|
|
|
|
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
| ||||||||||||
| 1 | Becker | 2003 | Siemens | 4 | 120 | 0.5 | 250 | 11 | 45 | (34-87) | Ex-vivo | Coronary | Pathology | 15 | 47 | 16 | 104 ± 28 | [ |
| 2 | Brodoefel | 2008 | Siemens | 64 | 120 | 0.6 | NA | 13 | 92 | 65 | In-vivo | Coronary | IVUS | NA | (-10-66) | NA | (67-153) | [ |
| 3 | Carrascosa | 2003 | Philips | 4 | 120 | 1 | NA | 30 | NA | NA | In-vivo | Coronary | IVUS | 105 | 75.73 | 14 | 148.61 | [ |
| 4 | Carrascosa | 2006 | Philips | 4 | 120 | 1 | NA | 40 | 80 | 52 (33-86) | In-vivo | Coronary | IVUS | 188 | 71.5 | 45 | 116.3 | [ |
| 5 | Caussin | 2004 | Siemens | 16 | NA | NA | NA | 21 | 52 | 58 | In-vivo | Coronary | IVUS | 12 | 12 | 4 | 63.8 | [ |
| 6 | Chopard | 2010 | Philips | 64 | 120 | 0.625 | NA | 21 | NA | NA | Ex-vivo | Coronary | Pathology | 20 | 70 | 42 | 83 | [ |
| 7 | de Weert | 2005 | Siemens | 16 | 140 | 0.75 | 0 | 21 | 81 | 64.7 (41-81) | Ex-vivo | Carotid | Pathology | 35 | 45 | 28 | 79 | [ |
| 8 | de Weert | 2006 | Siemens | 16 | 120 | 0.75 | ~400 | 15 | 40 | 70.3 (62-84) | In-vivo | Carotid | Pathology | 31 | 25 | 53 | 88 | [ |
| 9 | Estes | 1998 | Siemens | 1 | NA | 3 | 150-300 | 20 | 80 | 74 (57-85) | In-vivo | Carotid | Pathology | NA | 39 | NA | 90 | [ |
| 10 | Ferencik | 2006 | Siemens | 16 | 120 | 0.75 | 250 | 6 | 67 | 77 | Ex-vivo | Coronary | OCT | 41 | 29 | 40 | 101 | [ |
| 11 | Galonska | 2008 | GE | 16 | 120 | 0.625 | 308 | 30 | 67 | 61.5 | Ex-vivo | Coronary | Pathology | 33 | (26-67) median: 44 | 21 | (37-124) median: 67 | [ |
| 12 | Hur | 2009 | Siemens | 64 | 120 | 0.6 | NA | 39 | 72 | 59 (45-74) | In-vivo | Coronary | IVUS | 10 | 54 | 11 | 82 | [ |
| 13 | Iriart | 2007 | Siemens | 16 | 120 | 0.75 | NA | 20 | 85 | 53 | In-vivo | Coronary | IVUS | NA | 38 | NA | 94 | [ |
| 14 | Jin | 2006 | Siemens | 16 | 120 | NA | NA | 49 | 55 | NA | In-vivo | Carotid | DUS | NA | 6 | NA | 51 | [ |
| 15 | Kim | 2009 | GE | 64 | 120 | 0.625 | NA | 42 | 48 | 66 | In-vivo | Coronary | IVUS | 28 | 52.9 | 43 | 98.6 | [ |
| 16 | Kitagawa | 2007 | GE | 64 | 120 | 0.625 | ~350 | 21 | 76 | 66 | In-vivo | Coronary | IVUS | 25 | 18 | 13 | 67 | [ |
| 17 | Kopp | 2001 | Siemens | 4 | 120 | 1 | NA | 6 | 67 | 60 | In-vivo | Coronary | IVUS | 2 | 0.5 | 2 | 67 | [ |
| 18 | Leber | 2004 | Siemens | 16 | 120 | 0.75 | NA | 37 | NA | NA | In-vivo | Coronary | IVUS | 62 | 49 | 87 | 91 | [ |
| 19 | Leschka | 2010 | Siemens | 64 | 120 | 0.6 | 300 | 25 | 72 | 72 | Ex-vivo | Coronary | Pathology | 91 | 40 | 43 | 91 | [ |
| 20 | Marwan | 2011 | Siemens | 64 | 120 | 0.6 | NA | 40 | 75 | 59 | In-vivo | Coronary | IVUS | 15 | 67 | 40 | 96 | [ |
| 21 | Motoyama | 2007 | Toshiba | 16 | 135 | 0.5 | 258 | 37 | 84 | 66 | In-vivo | Coronary | IVUS | 18 | 10.6 | 40 | 78.1 | [ |
| 22 | Nikolaou | 2004 | Siemens | 4 | 120 | 0.5 | 250 | 17 | 65 | (38-86) | Ex-vivo | Coronary | Pathology | 16 | 45 | 21 | 97 | [ |
| 23 | Nikolaou | 2004 | Siemens | 4 | 120 | 0.5 | 242 | 13 | 62 | (34-87) | Ex-vivo | Coronary | Pathology | 10 | 47 | 11 | 87 | [ |
| 24 | Pohle | 2007 | Siemens | 16 | 120 | 0.75 | NA | 32 | 72 | 59 | In-vivo | Coronary | IVUS | 84 | 58 | 42 | 121 | [ |
| 25 | Qiu | 2006 | Philips | 64 | 120-140 | 0.625 | NA | 6 | 67 | 77.5 | In-vivo | Coronary | IVUS | 2 | -21.5 | 4 | 85.3 | [ |
| 26 | Sakakura | 2006 | Toshiba | 16 | 135 | 0.5 | NA | 16 | 69 | 63 | In-vivo | Coronary | IVUS | 6 | 50.6 | 11 | 131 | [ |
| 27 | Schroeder | 2001 | Siemens | 4 | 140 | 1 | NA | 15 | 87 | 58 | In-vivo | Coronary | IVUS | 12 | 14 | 5 | 91 | [ |
| 28 | Schroeder | 2004 | Siemens | 4 | 140 | 1 | 182 | 12 | NA | 63 | Ex-vivo | Coronary | Pathology | 6 | 42 | 6 | 70 | [ |
| 29 | Schroeder | 2004 | Siemens | 16 | 120 | 0.75 | 237 | 9 | NA | NA | Ex-vivo | Popliteal | Pathology | 13 | 51 | 18 | 126 | [ |
| 30 | Shen | 2010 | GE | 64 | 120 | 0.6 | NA | 91 | 58.2 | 64.78 | In-vivo | Coronary | IVUS | 6 | 52.52 | 36 | 108.32 | [ |
| 31 | Soeda | 2011 | Siemens | 64 | 120 | 0.6 | NA | 17 | 82.4 | 63.5 | In-vivo | Coronary | OCT | 78 | 28.9 | 42 | 77.5 | [ |
| 32 | Sun | 2008 | Toshiba | 64 | 120-135 | 0.5 | 398 | 26 | 65 | 56 | In-vivo | Coronary | IVUS | NA | 79 | NA | 90 + 27 | [ |
| 33 | Tanami | 2010 | GE | 32 | 80 | 0.625 | 0 | 15 | 73.3 | 72 | Ex-vivo | Coronary | Pathology | 39 | 20.5 | 30 | 28.1 | [ |
| 100 | 21.8 | 27.8 | ||||||||||||||||
| 120 | 23.1 | 27.1 | ||||||||||||||||
| 140 | 23.9 | 27.3 | ||||||||||||||||
| 34 | Wintermark | 2008 | GE | 16 | 120 | 0.625 | NA | 8 | 100 | 61 (55-69) | In-vivo | Carotid | Pathology | NA | 32.6 | NA | 46.4 | [ |
| 35 | Wu | 2007 | GE | 16 | 120 | 1.25 | NA | 30 | 73 | 58 (43-75) | In-vivo | Coronary | IVUS | 16 | 23 | 19 | 69 | [ |
| 36 | Xiao | 2007 | GE | 16 | 120 | 0.625 | NA | 25 | NA | (50-72) | Ex-vivo | Coronary | Pathology | 13 | 53 | 10 | 106 | [ |
| Toshiba | 64 | 120 | 0.5 | 51 | 110 | |||||||||||||
Notes:1. Values in the columns Lumen Contrast, Age, and Plaque Values are in means, with the range in brackets.
2. *: Values were self-calculated
3. NA: data were not available
Figure 2HU criteria for lipid-rich and fibrous plaques versus the reported lumen contrast-enhancement.
Pooled HU-criteria.
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||
| Study | Ex-vivo | 15 | 429 | 36 | Yes | 365 | 73 | Yes |
| design | In-vivo | 18 | 701 | 53 | 511 | 96 | ||
| Vessel | Coronary | 30 | 1051 | 47 | Yes | 777 | 85 | No |
| Type | Other Arteries | 3 | 79 | 38 | 99 | 92 | ||
| Brands | GE | 9 | 244 | 28 | Yes | 241 | 61 | Yes |
| Philips | 4 | 315 | 72 | 105 | 106 | |||
| Siemens | 17 | 534 | 41 | 469 | 94 | |||
| Toshiba | 3 | 37 | 31 | 61 | 93 | |||
| Rows | 4 | 8 | 354 | 67 | Yes | 120 | 108 | Yes |
| 16 | 11 | 332 | 42 | 352 | 95 | |||
| 32 | 4 | 156 | 22 | 120 | 28 | |||
| 64 | 9 | 288 | 41 | 284 | 91 | |||
| Voltage | <120 | 2 | 78 | 21 | Yes | 60 | 28 | Yes |
| (kV) | 120 | 23 | 921 | 52 | 688 | 94 | ||
| >120 | 6 | 116 | 29 | 120 | 71 | |||
| Collimation | <0.6 | 6 | 78 | 39 | Yes | 109 | 95 | Yes |
| width | 0.6-0.7 | 14 | 444 | 34 | 404 | 72 | ||
| (mm) | 0.7-0.8 | 6 | 266 | 46 | 268 | 98 | ||
| >0.8 | 6 | 329 | 67 | 91 | 106 | |||
Note:1. Ns: total amount of studies included in the pooling calculation. There were studies excluded because of incomplete data needed for pooling calculation or unclear characteristics needed for classification.
2. Np : total amount of plaques ROIs, segments, or squares of the studies of similar characteristic used to make the mean+st dev
3. All comparisons between groups’ HU-criteria within one type of characteristics were significantly different (p≤0.05) except the 12 pairs marked with the same symbols (*, †, ‡, §, ||, #, **, † †, ‡ ‡, § §, ||||, and # #).
Figure 3Hierarchical classification of HU-criteria for lipid-rich plaques.
Figure 4Hierarchical classification of HU-criteria for fibrous plaques.
Comparison of HU-criteria for lipid-rich plaque between hierarchical-classified groups.
|
|
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| - | * | 1 | * | * | 2 | * | * | * | NA | NA | NA | * | * | * | 2 | * | * | * | * | * |
|
| * | - | 1 | * | * | 2 | * | * | * | NA | NA | NA | * | * | 2 | 2 | * | * | * | * | * | |
|
| 1 | 1 | - | 2 | 1 | 1 | 1 | 1 | 1 | NA | NA | NA | 1 | * | 1 | * | 1 | 1 | 1 | * | 1 | |
|
| * | * | 2 | - | * | 2 | * | * | * | NA | NA | NA | * | * | * | 2 | * | * | * | * | * | |
|
| * | * | 1 | * | - | 1 | * | 2 | * | NA | NA | NA | * | 2 | * | 1 | 2 | * | * | 2 | 2 | |
|
| 2 | 2 | 1 | 2 | 1 | - | 1 | * | 1 | NA | NA | NA | 1 | * | 1 | * | * | 2 | 2 | * | * | |
|
| * | * | 1 | * | * | 1 | - | 2 | * | NA | NA | NA | * | 2 | * | 1 | 2 | * | * | * | 2 | |
|
| * | * | 1 | * | 2 | * | 2 | - | 2 | NA | NA | NA | * | * | 1 | 2 | * | * | * | * | * | |
|
| * | * | 1 | * | * | 1 | * | 2 | - | NA | NA | NA | * | * | * | 1 | * | * | * | * | 2 | |
|
| NA | NA | NA | NA | NA | NA | NA | NA | NA | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
|
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
|
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
|
| * | * | 1 | * | * | 1 | * | * | * | NA | NA | NA | - | * | * | 1 | * | * | * | * | * | |
|
| * | * | * | * | 2 | * | 2 | * | * | NA | NA | NA | * | - | 2 | * | * | * | * | * | * | |
|
| * | 2 | 1 | * | * | 1 | * | 1 | * | NA | NA | NA | * | 2 | - | 1 | 1 | * | 2 | * | 1 | |
|
| 2 | 2 | * | 2 | 1 | * | 1 | 2 | 1 | NA | NA | NA | 1 | * | 1 | - | * | 1 | 2 | * | * | |
|
| * | * | 1 | * | 2 | * | 2 | * | * | NA | NA | NA | * | * | 1 | * | - | * | * | * | * | |
|
| * | * | 1 | * | * | 2 | * | * | * | NA | NA | NA | * | * | * | 1 | * | - | * | * | * | |
|
| * | * | 1 | * | * | 2 | * | * | * | NA | NA | NA | * | * | 2 | 2 | * | * | - | * | * | |
|
| * | * | * | * | 2 | * | * | * | * | NA | NA | NA | * | * | * | * | * | * | * | - | * | |
|
| * | * | 1 | * | 2 | * | 2 | * | 2 | NA | NA | NA | * | * | 1 | * | * | * | * | * | - | |
Note:1. Significantly different at p < 0.001
2. Significantly Different at p <= 0.05
* Not significantly different
NA Comparison cannot be made due to lack of data, i.e. amount of plaque
Comparison of HU-criteria for fibrous plaque between hierarchical-classified groups.
|
|
| ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| - | 2 | 1 | * | * | 2 | * | * | * | NA | NA | NA | * | * | 1 | * | * | * | 2 | * | 2 | * |
|
| 2 | - | 1 | * | * | * | * | 2 | * | NA | NA | NA | * | * | 1 | * | * | * | * | * | * | * | |
|
| 1 | 1 | - | * | * | 2 | 2 | 1 | 1 | NA | NA | NA | 1 | * | 1 | 1 | 2 | 2 | 2 | 1 | * | 2 | |
|
| * | * | * | - | * | * | * | * | * | NA | NA | NA | * | * | 2 | * | * | * | * | * | * | * | |
|
| * | * | * | * | - | * | * | * | * | NA | NA | NA | * | * | 2 | * | * | * | * | * | * | * | |
|
| 2 | * | 2 | * | * | - | * | 1 | * | NA | NA | NA | * | * | 1 | * | * | * | * | * | * | * | |
|
| * | * | 2 | * | * | * | - | * | * | NA | NA | NA | * | * | * | * | * | * | * | * | * | * | |
|
| * | 2 | 1 | * | * | 1 | * | - | * | NA | NA | NA | * | * | 1 | * | 2 | * | 2 | * | * | 2 | |
|
| * | * | 1 | * | * | * | * | * | - | NA | NA | NA | * | * | 1 | * | * | * | * | * | * | * | |
|
| NA | NA | NA | NA | NA | NA | NA | NA | NA | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
|
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
|
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
|
| * | * | 1 | * | * | * | * | * | * | NA | NA | NA | - | * | 1 | * | * | * | * | * | * | * | |
|
| * | * | * | * | * | * | * | * | * | NA | NA | NA | * | - | 1 | * | * | * | * | * | * | * | |
|
| 1 | 1 | 1 | 2 | 2 | 1 | * | 1 | 1 | NA | NA | NA | 1 | 1 | - | 1 | 1 | * | 1 | 1 | 1 | 1 | |
|
| * | * | 1 | * | * | * | * | * | * | NA | NA | NA | * | * | 1 | - | * | * | * | * | * | * | |
|
| * | * | 2 | * | * | * | * | 2 | * | NA | NA | NA | * | * | 1 | * | - | * | * | * | * | * | |
|
| * | * | 2 | * | * | * | * | * | * | NA | NA | NA | * | * | * | * | * | - | * | * | * | * | |
|
| 2 | * | 2 | * | * | * | * | 2 | * | NA | NA | NA | * | * | 1 | * | * | * | - | * | * | * | |
|
| * | * | 1 | * | * | * | * | * | * | NA | NA | NA | * | * | 1 | * | * | * | * | - | * | * | |
|
| 2 | * | * | * | * | * | * | * | * | NA | NA | NA | * | * | 1 | * | * | * | * | * | - | * | |
|
| * | * | 2 | * | * | * | * | 2 | * | NA | NA | NA | * | * | 1 | * | * | * | * | * | * | - | |
Note:1. Significantly different at p < 0.001
2. Significantly different at p <= 0.05
* Not significantly different
NA Comparison cannot be made due to lack of data, i.e. amount of plaque
Figure 5The hierarchically grouped HU-criteria for lipid-rich and fibrous plaques along with their +/-1 standard deviation.
The blue and purple rounded-boxes bound the groups that give non-significant different HU-criteria and therefore pooled, for lipid-rich and fibrous plaque, respectively.